Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about the company's own repeatable business unit size escalating. We need to look for management's own words conveying a comparison against the company's recent past, that it's already real and recurring, and that it's early. Scan the transcript. Management discusses Shopee, SeaMoney, Garena. They talk about growth, market share, unit economics. They mention that Shopee's EBITDA loss per order improved, but that's about profitability, not deal size. They talk about GMV growth, but that's volume. They mention that in Brazil, they have over 2 million sellers, but that's scale. They talk about SeaMoney revenue growth, but that's overall. Is there any mention of deals, orders, contracts, projects, customers, sites, or programs getting individually larger? They mention that Shopee Mall has more brand partners, but that's more partners, not necessarily larger per partner. They mention that they onboarded more brand partners like Kiehl's, Kate Spade, but that's just examples. They talk about digital financial services, but again, it's about adoption and revenue growth. The question is specifically about the unit size of the company's own repeatable business escalating. For example, if they said "our average order value has increased" or "our new customers are starting at higher levels" or "we are now signing larger contracts" etc. I don't see any such statement. Management does mention that they are seeing improvements in unit economics, but that's about cost per order, not about the size of each order. They also mention that they are expanding into new markets, but that's not about the same offering getting bigger. They also mention that they are seeing stabilization in Free Fire user trends, but that's not about deal size. There is no mention of successive engagements of the same kind coming in at progressively larger size. The growth described is primarily volume-driven: more users, more orders, more revenue. They don't say that each new order is bigger than before, or that new customers are starting at higher levels, or that they are signing larger contracts. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.